Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2019-04-26 Interim / Quarterly Rep…
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2019
2019-04-26 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release about financial results for the first quarter ended March 31, 2019. It also states that a conference call will be held to discuss these results. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The length is 3913 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results and referencing a press release and conference call is best classified as an Earnings Release (ER).
2019-04-25 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-16 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document does not contain financial statements or detailed financial analysis, but rather is related to shareholder voting and meeting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short and it is not an announcement of a report but the proxy materials themselves.
2019-04-10 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-10 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.